These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 33135391)

  • 1. A phase 1 study of combined guadecitabine and cisplatin in platinum refractory germ cell cancer.
    Albany C; Fazal Z; Singh R; Bikorimana E; Adra N; Hanna NH; Einhorn LH; Perkins SM; Sandusky GE; Christensen BC; Keer H; Fang F; Nephew KP; Spinella MJ
    Cancer Med; 2021 Jan; 10(1):156-163. PubMed ID: 33135391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Refractory testicular germ cell tumors are highly sensitive to the second generation DNA methylation inhibitor guadecitabine.
    Albany C; Hever-Jardine MP; von Herrmann KM; Yim CY; Tam J; Warzecha JM; Shin L; Bock SE; Curran BS; Chaudhry AS; Kim F; Sandusky GE; Taverna P; Freemantle SJ; Christensen BC; Einhorn LH; Spinella MJ
    Oncotarget; 2017 Jan; 8(2):2949-2959. PubMed ID: 27936464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Phase I Clinical Trial of Guadecitabine and Carboplatin in Platinum-Resistant, Recurrent Ovarian Cancer: Clinical, Pharmacokinetic, and Pharmacodynamic Analyses.
    Matei D; Ghamande S; Roman L; Alvarez Secord A; Nemunaitis J; Markham MJ; Nephew KP; Jueliger S; Oganesian A; Naim S; Su XY; Keer H; Azab M; Fleming GF
    Clin Cancer Res; 2018 May; 24(10):2285-2293. PubMed ID: 29500276
    [No Abstract]   [Full Text] [Related]  

  • 4. Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial.
    Kantarjian HM; Roboz GJ; Kropf PL; Yee KWL; O'Connell CL; Tibes R; Walsh KJ; Podoltsev NA; Griffiths EA; Jabbour E; Garcia-Manero G; Rizzieri D; Stock W; Savona MR; Rosenblat TL; Berdeja JG; Ravandi F; Rock EP; Hao Y; Azab M; Issa JJ
    Lancet Oncol; 2017 Oct; 18(10):1317-1326. PubMed ID: 28844816
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial.
    Garcia-Manero G; Roboz G; Walsh K; Kantarjian H; Ritchie E; Kropf P; O'Connell C; Tibes R; Lunin S; Rosenblat T; Yee K; Stock W; Griffiths E; Mace J; Podoltsev N; Berdeja J; Jabbour E; Issa JJ; Hao Y; Keer HN; Azab M; Savona MR
    Lancet Haematol; 2019 Jun; 6(6):e317-e327. PubMed ID: 31060979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination chemotherapy with gemcitabine plus oxaliplatin in patients with intensively pretreated or refractory germ cell cancer: a study of the German Testicular Cancer Study Group.
    Kollmannsberger C; Beyer J; Liersch R; Schoeffski P; Metzner B; Hartmann JT; Rick O; Stengele K; Hohloch K; Spott C; Kanz L; Bokemeyer C
    J Clin Oncol; 2004 Jan; 22(1):108-14. PubMed ID: 14701772
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study.
    Issa JJ; Roboz G; Rizzieri D; Jabbour E; Stock W; O'Connell C; Yee K; Tibes R; Griffiths EA; Walsh K; Daver N; Chung W; Naim S; Taverna P; Oganesian A; Hao Y; Lowder JN; Azab M; Kantarjian H
    Lancet Oncol; 2015 Sep; 16(9):1099-1110. PubMed ID: 26296954
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I Trial of DNA Methyltransferase Inhibitor Guadecitabine Combined with Cisplatin and Gemcitabine for Solid Malignancies Including Urothelial Carcinoma (SPIRE).
    Crabb SJ; Danson S; Catto JWF; Hussain S; Chan D; Dunkley D; Downs N; Marwood E; Day L; Saunders G; Light M; Whitehead A; Ellis D; Sarwar N; Enting D; Birtle A; Johnson B; Huddart R; Griffiths G
    Clin Cancer Res; 2021 Apr; 27(7):1882-1892. PubMed ID: 33472913
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of Disulfiram and Cisplatin in Refractory Germ Cell Tumors. The GCT-SK-006 phase II trial.
    Mego M; Svetlovska D; Angelis V D; Kalavska K; Lesko P; Makovník M; Obertova J; Orszaghova Z; Palacka P; Rečková M; Rejlekova K; Z SM; Mardiak J; Chovanec M
    Invest New Drugs; 2022 Oct; 40(5):1080-1086. PubMed ID: 35763178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Irinotecan in patients with relapsed or cisplatin-refractory germ cell cancer: a phase II study of the German Testicular Cancer Study Group.
    Kollmannsberger C; Rick O; Klaproth H; Kubin T; Sayer HG; Hentrich M; Welslau M; Mayer F; Kuczyk M; Spott C; Kanz L; Bokemeyer C
    Br J Cancer; 2002 Sep; 87(7):729-32. PubMed ID: 12232755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination chemotherapy with gemcitabine, oxaliplatin, and paclitaxel in patients with cisplatin-refractory or multiply relapsed germ-cell tumors: a study of the German Testicular Cancer Study Group.
    Bokemeyer C; Oechsle K; Honecker F; Mayer F; Hartmann JT; Waller CF; Böhlke I; Kollmannsberger C;
    Ann Oncol; 2008 Mar; 19(3):448-53. PubMed ID: 18006893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial.
    Fizazi K; Pagliaro L; Laplanche A; Fléchon A; Mardiak J; Geoffrois L; Kerbrat P; Chevreau C; Delva R; Rolland F; Theodore C; Roubaud G; Gravis G; Eymard JC; Malhaire JP; Linassier C; Habibian M; Martin AL; Journeau F; Reckova M; Logothetis C; Culine S
    Lancet Oncol; 2014 Dec; 15(13):1442-1450. PubMed ID: 25456363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brief report: phase II multicenter study of temozolomide in patients with cisplatin-resistant germ cell tumors.
    Maroto P; Huddart R; Garcia del Muro X; Horwich A; Paz Ares L; Aparicio J; Germa-Lluch JR
    Oncology; 2011; 80(3-4):219-22. PubMed ID: 21734411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumoral activity of oxaliplatin/cisplatin-based combination therapy in cisplatin-refractory germ cell cancer patients.
    Soulié P; Garrino C; Bensmaïne MA; Bekradda M; Brain E; Di Palma M; Goupil A; Misset JL; Cvitkovic E
    J Cancer Res Clin Oncol; 1999 Dec; 125(12):707-11. PubMed ID: 10592105
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Salvage chemotherapy with paclitaxel, ifosphamide and nedaplatin for relapsed or refractory germ cell cancer].
    Nomoto T; Mizutani Y; Mikami K; Nakamura T; Nakanishi H; Kawauchi A; Miki T
    Nihon Hinyokika Gakkai Zasshi; 2006 May; 97(4):630-5. PubMed ID: 16768143
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An open-label, multicenter phase II trial of capecitabine in patients with cisplatin-refractory or relapsed germ cell tumors.
    Oechsle K; Honecker F; Kollmannsberger C; Rick O; Grünwald V; Mayer F; Hartmann JT; Bokemeyer C
    Anticancer Drugs; 2007 Mar; 18(3):273-6. PubMed ID: 17264758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase 1, dose-escalation study of guadecitabine (SGI-110) in combination with pembrolizumab in patients with solid tumors.
    Papadatos-Pastos D; Yuan W; Pal A; Crespo M; Ferreira A; Gurel B; Prout T; Ameratunga M; Chénard-Poirier M; Curcean A; Bertan C; Baker C; Miranda S; Masrour N; Chen W; Pereira R; Figueiredo I; Morilla R; Jenkins B; Zachariou A; Riisnaes R; Parmar M; Turner A; Carreira S; Yap C; Brown R; Tunariu N; Banerji U; Lopez J; de Bono J; Minchom A
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35717027
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Phase I Trial of a Guadecitabine (SGI-110) and Irinotecan in Metastatic Colorectal Cancer Patients Previously Exposed to Irinotecan.
    Lee V; Wang J; Zahurak M; Gootjes E; Verheul HM; Parkinson R; Kerner Z; Sharma A; Rosner G; De Jesus-Acosta A; Laheru D; Le DT; Oganesian A; Lilly E; Brown T; Jones P; Baylin S; Ahuja N; Azad N
    Clin Cancer Res; 2018 Dec; 24(24):6160-6167. PubMed ID: 30097434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Guadecitabine vs TC in relapsed/refractory AML after intensive chemotherapy: a randomized phase 3 ASTRAL-2 trial.
    Roboz GJ; Sanz G; Griffiths EA; Yee K; Kantarjian H; Récher C; Byrne MT; Patkowska E; Kim HJ; Thomas X; Moors I; Stock W; Illés Á; Fenaux P; Miyazaki Y; Yamauchi T; O'Connell CL; Hao Y; Keer HN; Azab M; Döhner H
    Blood Adv; 2024 Apr; 8(8):2020-2029. PubMed ID: 38231126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response to anti-programmed cell death protein-1 antibodies in men treated for platinum refractory germ cell cancer relapsed after high-dose chemotherapy and stem cell transplantation.
    Zschäbitz S; Lasitschka F; Hadaschik B; Hofheinz RD; Jentsch-Ullrich K; Grüner M; Jäger D; Grüllich C
    Eur J Cancer; 2017 May; 76():1-7. PubMed ID: 28262583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.